Leerink Partnrs Has Bullish Outlook for Bruker Q1 Earnings

Bruker Co. (NASDAQ:BRKR) – Research analysts at Leerink Partnrs lifted their Q1 2025 earnings per share (EPS) estimates for Bruker in a report released on Wednesday, April 16th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $0.50 per share for the quarter, up from their previous estimate of $0.41. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker’s Q2 2025 earnings at $0.54 EPS, Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.87 EPS, FY2025 earnings at $2.55 EPS, Q1 2026 earnings at $0.64 EPS, Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.94 EPS, FY2026 earnings at $2.92 EPS and FY2027 earnings at $3.38 EPS.

Several other equities research analysts also recently issued reports on the company. Wells Fargo & Company cut their price target on Bruker from $75.00 to $60.00 and set an “overweight” rating for the company in a report on Thursday. Stifel Nicolaus cut their price objective on shares of Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a research report on Friday, February 14th. Citigroup lowered their target price on Bruker from $75.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Finally, Barclays lowered their price target on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $36.28 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker has a twelve month low of $34.10 and a twelve month high of $83.32. The business’s 50 day moving average price is $44.81 and its two-hundred day moving average price is $53.97. The company has a market cap of $5.50 billion, a PE ratio of 47.74, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend was Monday, March 17th. Bruker’s payout ratio is 26.32%.

Institutional Investors Weigh In On Bruker

Hedge funds have recently made changes to their positions in the stock. London Co. of Virginia boosted its position in Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company’s stock valued at $245,820,000 after buying an additional 1,843,294 shares in the last quarter. Brown Advisory Inc. grew its position in Bruker by 10.1% during the 4th quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company’s stock worth $118,806,000 after acquiring an additional 185,912 shares during the last quarter. Geode Capital Management LLC increased its holdings in Bruker by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company’s stock worth $118,081,000 after purchasing an additional 20,273 shares in the last quarter. FIL Ltd boosted its stake in shares of Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company’s stock valued at $114,978,000 after purchasing an additional 1,420,102 shares in the last quarter. Finally, Sculptor Capital LP grew its holdings in shares of Bruker by 484.1% during the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company’s stock worth $100,476,000 after purchasing an additional 1,420,569 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.